OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property assets from ...
NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a biotechnology firm focusing on cancer immunotherapies and targeted drug conjugates, with a current market capitalization of $37 million, has provided a ...
Wear OS 6 will likely transform Android watches with Gemini tricks and new fitness coaching. Here's what we know (and hope to ...
The assets being acquired include a Phase 2 lung cancer and Phase1 prostate cancer program, in addition to the gaining direct ownership of the underlying IP related to OS Therapies’ lead asset ...
These Samsung phones are confirmed to receive four generations of Android updates. Find out if yours is included!
As per the terms of the agreement, OS Therapies will pay an aggregate purchase price of $8 million. This will include $0.5 million in cash and $7.5 million worth of OS Therapies’ common shares.
OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback